On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19 subunit vaccine program) in non-human primates demonstrating rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants.